Published on 10/12/2025

SIP/Sterilization Links in Hybrid (SU + SS) Plants

In the complex landscape of biologics and Advanced Therapy Medicinal Products (ATMP) validation, understanding the role of aseptic controls within hybrid Single-Use (SU) and Stainless Steel (SS) systems is critical. This step-by-step guide will delve into the nuances of viral clearance validation, spiking studies, and the regulatory expectations surrounding closed systems. Additionally, it will cover potency identity critical quality attributes (CQAs), chain of identity custody, and Performance Qualification (PQ) along with Continued Process Verification (CPV) tailoring specific to ATMPs.

Understanding Hybrid SU and SS Systems

Hybrid systems that combine Single-Use and Stainless Steel components present unique challenges and opportunities for aseptic processing. Single-Use Systems (SUS) offer flexibility, reduced cross-contamination risk, and streamlined workflows, making them increasingly common in modern biopharmaceutical manufacturing. However, these systems must be carefully integrated with traditional Stainless Steel configurations to maintain the integrity of the aseptic environment.

The selection and validation of these systems must align with current regulatory guidelines, such as those outlined in ICH Q5A(R2), which emphasizes the need for comprehensive viral clearance validation strategies to ensure product safety. This involves understanding how to effectively link Sterilization-In-Place (SIP) processes with Hybrid SU and SS systems.

Step 1: Risk Assessment and Preliminary Considerations

The first step in managing viral clearance and aseptic controls in hybrid systems is conducting a thorough risk assessment. This assessment should encompass:

• Process Flow Mapping: Document the flow of material through the hybrid system to identify potential contamination points.
• Material Compatibility: Assess the chemical and physical compatibility of Single-Use components with Stainless Steel systems.
• Equipment Design Evaluation: Ensure that the equipment is designed to allow for effective SIP processes without introducing contamination risks.

Understanding the interactions between different system components will help in developing a robust validation strategy that meets the specific needs of the biologics being produced.

Step 2: Establishing Aseptic Controls via SIP

SIP is a critical operation for ensuring that both Single-Use and Stainless Steel components achieve the necessary sterility for aseptic processing. This step includes:

• SIP Procedure Development: Establish standardized procedures for SIP that take into account the materials and configurations of the hybrid system. Document parameters such as temperature, time, and pressure necessary for effective sterilization.
• In-Process Monitoring: Implement monitoring strategies to ensure proper SIP conditions are met. This may include using bio-indicators or temperature and pressure sensors integrated into the process.

Following the development of these procedures, it is crucial to validate the effectiveness of SIP processes through a series of qualification studies, incorporating worst-case scenarios as outlined in relevant guidelines.

Step 3: Conducting Viral Clearance Validation and Spiking Studies

Once SIP processes are established, the next step is to conduct viral clearance validation. This involves performing spiking studies to evaluate the ability of the filtration and sterilization processes to remove and inactivate viral contaminants.

This step can be broken down into the following tasks:

• Defining Viral Challenge: Select appropriate viral models that reflect the types of contaminants that may pose a risk to product safety. Commonly used viruses include PPV and MMV, which mimic potential safety risks during processing.
• Spiking Execution: Conduct spiking studies by intentionally introducing these viral models into the process streams, followed by analysis to determine the level of viral reduction achieved.
• Data Analysis: Analyze the results to calculate the log reduction values and determine if the viral clearance meets the established safety margins defined in FDA process validation guidelines.

Documenting the results of these studies will provide evidence of the integrity of viral clearance across the combined SU and SS systems.

Step 4: Identifying Potency Identity CQAs and Chain of Identity Custody

With viral clearance established, attention must turn towards evaluating the critical quality attributes (CQAs) of the biologics produced. Specifically, potency identity CQAs are essential for ensuring that the products not only meet safety standards but also therapeutic efficacy.

Two focal areas in this step include:

• Defining Potency Identity CQAs: These attributes may include factors such as biological activity, targeting specificity, and molecular integrity. Adequate methods for assessing these characteristics must be established prior to product release.
• Chain of Identity Custody (COI/COC): Ensure that all materials used in the production process are traceable and managed appropriately, mitigating risks associated with contamination or mix-ups that can compromise product integrity.

Establishing and maintaining a documented chain of identity is crucial for compliance with quality system regulations and will facilitate traceability across production batches.

Step 5: Performance Qualification (PQ) and Continued Process Verification (CPV) Tailoring for ATMPs

The final step in the validation lifecycle involves the implementation of Performance Qualification (PQ) and Continued Process Verification (CPV). For ATMPs, yoThese practices are vital in confirming that the integrated hybrid system continuously operates within predetermined specifications and tolerances.

This step encompasses:

• PQ Execution: Conduct PQ tests on the hybrid system after installation and during routine operations to verify that the system consistently achieves the established performance criteria.
• CPV Strategy Development: Tailor a CPV plan specifically for ATMPs to monitor critical process parameters and CQAs continuously. This involves defining how data will be collected, analyzed, and acted upon throughout the lifecycle of the product.

Regularly reviewing CPV data not only ensures compliance but also facilitates prompt actions based on emerging trends, thus enhancing the overall reliability of the aseptic control systems.

Conclusion

In conclusion, the integration of SIP and sterilization processes within hybrid SU and SS systems requires a comprehensive validation approach that adheres to the stringent guidelines set forth by regulatory bodies such as the FDA, EMA, and MHRA. By following this step-by-step guide, professionals involved in biopharmaceutical production can ensure that their viral clearance validation strategies are robust, their aseptic controls are effective, and their product quality meets the highest industry standards.

Maintaining a thorough understanding of regulatory expectations alongside proper documentation and continuous monitoring will fortify the safety and efficacy of biologics produced within hybrid processing frameworks, ultimately supporting successful market approval and patient safety.